{"id":"NCT00813709","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)","officialTitle":"Double-blind Extension of the Study 27025 (REFLEX) to Obtain Long-term Follow-up Data in Patients With Clinically Definite MS and Patients With a First Demyelinating Event at High Risk of Converting to MS, Treated With Rebif速 New Formulation (REFLEXION)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-08","completion":"2013-09","firstPosted":"2008-12-23","resultsPosted":"2013-10-28","lastUpdate":"2017-03-08"},"enrollment":402,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Clinically Isolated Syndrome"],"interventions":[{"type":"DRUG","name":"RNF","otherNames":["Rebif速"]},{"type":"DRUG","name":"RNF","otherNames":["Rebif速"]},{"type":"DRUG","name":"RNF","otherNames":["Rebif速"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"RNF 44 mcg thrice weekly","type":"ACTIVE_COMPARATOR"},{"label":"RNF 44 mcg once weekly and placebo","type":"ACTIVE_COMPARATOR"},{"label":"Placebo/RNF 44 mcg thrice weekly","type":"ACTIVE_COMPARATOR"}],"summary":"REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a first demyelinating event at high risk of converting to MS, treated with fetal bovine serum \\[FBS\\]-free/human serum albumin \\[HSA\\]-free formulation of interferon \\[IFN\\]-beta-1a (RNF).","primaryOutcome":{"measure":"Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score up to 36 Months","timeFrame":"Baseline (Day 1 of Study 27025) up to 36 Months","effectByArm":[{"arm":"Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population)","deltaMin":41.3,"sd":null},{"arm":"RNF 44 Mcg Once Weekly (Integrated ITT Population)","deltaMin":27.6,"sd":null},{"arm":"RNF 44 Mcg Thrice Weekly (Integrated ITT Population)","deltaMin":27.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.002"},{"comp":"OG000 vs OG001","p":"0.006"},{"comp":"OG001 vs OG002","p":"0.941"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":57,"countries":["Argentina","Austria","Belgium","Bulgaria","Canada","Croatia","Czechia","Estonia","Finland","France","Germany","Greece","Israel","Italy","Latvia","Lebanon","Morocco","Poland","Portugal","Romania","Russia","Serbia","Slovakia","Spain"]},"refs":{"pmids":["28039317"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":84},"commonTop":["Influenza like illness","Headache","Nasopharyngitis","Upper respiratory tract infection","Injection site erythema"]}}